| Robin Normand, CRNP | |
|
251 N Bayou St, Mobile, AL 36603-5827 | |
| (251) 690-8158 | |
| (251) 544-2188 |
| Full Name | Robin Normand |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 18 Years |
| Location | 251 N Bayou St, Mobile, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720291636 | NPI | - | NPPES |
| 630000013 | Medicaid | AL | |
| 630004013 | Medicaid | AL | |
| 011846 | Other | AL | MEDICARE GROUP NUMBER |
| 1063439065 | Other | AL | NPI SITE MCARE GROUP PAYEE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Usa Health University Hospital | Mobile, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mobile County Board Of Health | 9931208386 | 24 |
| Usa Health Physician Billing Services Llc | 9931436912 | 266 |
News Archive
Sealing pits and fissures with a resin-based material can arrest the progression of noncavitated dentinal occlusal caries, show results of a 36-month clinical trial.
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Just as the repeal positions of some big insurers are becoming more clear, more details on the Democrats' strategy to defend the law are emerging.
The development of new drugs to treat and prevent HIV/AIDS depends on understanding the basic biology of how the virus infects human cells. For 25 years, researchers supported primarily by NIH's National Institute of General Medical Sciences (NIGMS) have been generating the structures of key viral proteins, revealing important insights into the virus's mechanisms and, more importantly, its Achilles' heels.
› Verified 8 days ago
| Entity Name | University Of South Alabama |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992746838 PECOS PAC ID: 3072425149 Enrollment ID: O20040115000773 |
News Archive
Sealing pits and fissures with a resin-based material can arrest the progression of noncavitated dentinal occlusal caries, show results of a 36-month clinical trial.
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Just as the repeal positions of some big insurers are becoming more clear, more details on the Democrats' strategy to defend the law are emerging.
The development of new drugs to treat and prevent HIV/AIDS depends on understanding the basic biology of how the virus infects human cells. For 25 years, researchers supported primarily by NIH's National Institute of General Medical Sciences (NIGMS) have been generating the structures of key viral proteins, revealing important insights into the virus's mechanisms and, more importantly, its Achilles' heels.
› Verified 8 days ago
| Entity Name | Franklin Primary Health Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679532303 PECOS PAC ID: 1658356308 Enrollment ID: O20040618000827 |
News Archive
Sealing pits and fissures with a resin-based material can arrest the progression of noncavitated dentinal occlusal caries, show results of a 36-month clinical trial.
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Just as the repeal positions of some big insurers are becoming more clear, more details on the Democrats' strategy to defend the law are emerging.
The development of new drugs to treat and prevent HIV/AIDS depends on understanding the basic biology of how the virus infects human cells. For 25 years, researchers supported primarily by NIH's National Institute of General Medical Sciences (NIGMS) have been generating the structures of key viral proteins, revealing important insights into the virus's mechanisms and, more importantly, its Achilles' heels.
› Verified 8 days ago
| Entity Name | Mobile County Board Of Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063439065 PECOS PAC ID: 9931208386 Enrollment ID: O20180913000728 |
News Archive
Sealing pits and fissures with a resin-based material can arrest the progression of noncavitated dentinal occlusal caries, show results of a 36-month clinical trial.
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Just as the repeal positions of some big insurers are becoming more clear, more details on the Democrats' strategy to defend the law are emerging.
The development of new drugs to treat and prevent HIV/AIDS depends on understanding the basic biology of how the virus infects human cells. For 25 years, researchers supported primarily by NIH's National Institute of General Medical Sciences (NIGMS) have been generating the structures of key viral proteins, revealing important insights into the virus's mechanisms and, more importantly, its Achilles' heels.
› Verified 8 days ago
| Entity Name | Usa Health Physician Billing Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720645468 PECOS PAC ID: 9931436912 Enrollment ID: O20190814000827 |
News Archive
Sealing pits and fissures with a resin-based material can arrest the progression of noncavitated dentinal occlusal caries, show results of a 36-month clinical trial.
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Just as the repeal positions of some big insurers are becoming more clear, more details on the Democrats' strategy to defend the law are emerging.
The development of new drugs to treat and prevent HIV/AIDS depends on understanding the basic biology of how the virus infects human cells. For 25 years, researchers supported primarily by NIH's National Institute of General Medical Sciences (NIGMS) have been generating the structures of key viral proteins, revealing important insights into the virus's mechanisms and, more importantly, its Achilles' heels.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robin Normand, CRNP 251 N Bayou St, Mobile, AL 36603-5827 Ph: (251) 690-8158 | Robin Normand, CRNP 251 N Bayou St, Mobile, AL 36603-5827 Ph: (251) 690-8158 |
News Archive
Sealing pits and fissures with a resin-based material can arrest the progression of noncavitated dentinal occlusal caries, show results of a 36-month clinical trial.
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Just as the repeal positions of some big insurers are becoming more clear, more details on the Democrats' strategy to defend the law are emerging.
The development of new drugs to treat and prevent HIV/AIDS depends on understanding the basic biology of how the virus infects human cells. For 25 years, researchers supported primarily by NIH's National Institute of General Medical Sciences (NIGMS) have been generating the structures of key viral proteins, revealing important insights into the virus's mechanisms and, more importantly, its Achilles' heels.
› Verified 8 days ago